Twenty-five years of putting hard-to-explain molecules into easy-to-buy boxes. Now the box contains nitric oxide.
Mikael Svensson, on September 1, 2025, became Chief Executive Officer of SaNOtize Research and Development Corporation, a 22-person biotech in Vancouver that sells nitric oxide. The molecule is a gas. It won the Nobel Prize in Medicine in 1998. Your endothelial cells make small quantities of it every second. And now, thanks to a business plan that Svensson inherits rather than authored, it comes in a bottle called NOWONDER. His job is to sell it. He has done this kind of thing before.
Consumer health is a strange discipline. It sits between three older ones - pharmaceuticals, medical devices, and beauty - and it borrows the vocabulary of all three without belonging entirely to any of them. The person who runs a consumer health company has to read a clinical dossier in the morning and a shelf-space negotiation in the afternoon. There are perhaps a thousand such executives in the world. Svensson is one of them.
His résumé, if you plotted it on a chart, would look less like a ladder and more like a coastal road. There is Restylane, the hyaluronic acid dermal filler he helped push into worldwide expansion. There is Naftin, a topical antifungal for dermatology and podiatry practices. There is Mederma, the drugstore scar-care brand that everyone with a childhood scrape knows by name. There is VagiVital, which addresses a category that pharmaceutical marketing has historically preferred to whisper about. And there is INOmax, an inhaled nitric oxide therapy for newborns experiencing hypoxic respiratory failure, an FDA-approved drug he directed the launch of in both U.S. and European markets.
The last one matters, because it is the reason he now runs SaNOtize. The company was founded on the thesis that nitric oxide - the same molecule that INOmax delivers as a hospital-grade gas - has commercial life beyond the neonatal ICU. It has antimicrobial properties. It reduces viral load. It can be formulated into a spray. The scientific work was done. What SaNOtize needed was someone who had already done the walk from lab to launch. Someone who could talk to a regulator on Monday and a wholesaler on Tuesday and a consumer on Wednesday.
The company hired the operator who had done that with a related molecule, in a related space, on a related timeline. It was not a subtle bet.
He is the specific kind of executive who ships. Not invents. Not researches. Ships.
— A working characterizationA visual guide to the products Mikael Svensson has helped bring to market. Each is a different regulatory pathway, a different distribution channel, and a different customer.
SaNOtize describes itself as a global pharmaceutical company. That is generous, in the way that biotech language is often generous, because with 22 employees it is not exactly Pfizer. What it is, more precisely, is a small platform company with a specific chemical thesis and a broad product surface: a nasal spray for respiratory viruses, an onychomycosis gel, a wound infection treatment, a sinusitis therapy, and now a consumer nasal cleanser. Six shots at the same molecule.
The company's most famous moment came during the pandemic, when its Nitric Oxide Nasal Spray (NONS) was studied as a possible treatment for COVID-19 and licensed in India as FabiSpray. The regulatory acronym cascade is real: NONS, NORS, FabiSpray, NOWONDER. Each one is nitric oxide in a slightly different jar.
Svensson inherited all of it. His job is to sort the promising jars from the noisy ones, focus commercial resources, and, in the language of biotech operators everywhere, get to revenue. In April 2026, the FDA sent a warning letter regarding NOWONDER, arguing that the company was marketing what regulators considered an unapproved new drug. This is the kind of letter that any consumer-facing biotech CEO expects to eventually receive, and any consumer-facing biotech CEO responds to with a lawyer and a labeling change.
It is also the reason SaNOtize hired a launcher rather than a scientist.
Led worldwide expansion of the hyaluronic acid dermal filler franchise. The category that taught pharma how to sell to dermatologists and dermatologists how to sell to consumers.
Directed U.S. and European launch of the FDA-approved inhaled nitric oxide therapy for newborns with hypoxic respiratory failure. His first nitric oxide product, and the through-line to today.
Scaled the drugstore-shelf scar-care brand that a generation grew up seeing. The kind of ubiquity that becomes invisible.
Scaled the topical antifungal used in dermatology and podiatry. A quieter category, but a real prescription business.
Commercial work on a vaginal moisturizer category that consumer-health marketing historically approached with tongs. He did not.
The consumer nasal cleanser at the center of the SaNOtize commercial story. His current assignment.
Biotech-to-consumer is a well-known migration path with a poor completion rate. Companies that hold clinical-grade IP often assume that the retail channel will be, in the polite phrase, adjacent. It is not adjacent. It is a different world with different physics: different regulatory posture, different distribution economics, different marketing rules, different customer intent. A drug that works in a hospital may fail spectacularly on a Target endcap, and vice versa.
Which is why the moment when a small biotech attempts consumer commercialization is the moment it typically hires someone with a scar collection. Svensson has the scar collection.
He also has the specific expertise of having launched a nitric oxide drug once already, which is worth more than it sounds. The molecule is unfamiliar to most physicians outside of critical-care neonatology, unfamiliar to virtually all consumers, and unfamiliar to most retailers and pharmacy chains. Explaining it is half the job. Svensson has explained it before.
His mandate at SaNOtize appears to be: pick the highest-potential product, focus commercial resources, navigate regulatory boundaries, and turn a Series B biotech into a commercial company. The April 2026 warning letter is a wrinkle. It is also, in a strange way, table stakes for the category.
He is Chief Executive Officer of SaNOtize Research and Development Corp., a Vancouver-based pharmaceutical and consumer health company commercializing nitric oxide.
September 1, 2025.
INOmax, Restylane, Naftin, Mederma, and VagiVital, across aesthetics, dermatology, OTC consumer health, women's health, and hospital pharmaceuticals.
A four-year post-secondary academic study in chemical engineering.
The Dallas/Fort Worth area in Texas, while SaNOtize is headquartered in Vancouver, British Columbia.